Current Medical Treatments for Uterine Fibroids

Chapter
Part of the Comprehensive Gynecology and Obstetrics book series (CGO)

Abstract

Uterine fibroids are benign tumors with a high prevalence rate and are considered the most common benign tumors in women of reproductive age. Surgical or medical treatment is necessary when symptoms, such as abnormal uterine bleeding, pelvic pain, and infertility, occur. Regarding hormonal therapies, a large number of GnRH agonist therapies have been employed. Current alternative treatments for the improvement of abnormal uterine bleeding and reduction of fibroid volume include GnRH antagonists, aromatase inhibitors, progestin, and selective progesterone receptor modulators, and their therapeutic effects have been studied.

Keywords

Uterine fibroid Medical treatment Selective progesterone receptor modulator 

References

  1. 1.
    Laughlin SK, et al. New directions in the epidemiology of uterine fibroids. Semin Reprod Med. 2010;28:204–17.CrossRefGoogle Scholar
  2. 2.
    Stewart EA. Uterine fibroids. Lancet. 2001;357:293–8.CrossRefGoogle Scholar
  3. 3.
    Buttram JVC, et al. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36:433.CrossRefGoogle Scholar
  4. 4.
    Manyonda IT, et al. Uterine artery embolization versus myomectomy: impact on quality of life-results of the FUME (Fibroids of the Uterus: Myomectomy versus Embolization) trial. Cardiovasc Intervent Radiol. 2012;35:530–6.CrossRefGoogle Scholar
  5. 5.
    Stewart EA, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril. 2006;85:22–9.CrossRefGoogle Scholar
  6. 6.
    Ishikawa H, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151:2433–42.CrossRefGoogle Scholar
  7. 7.
    Taylor DK, et al. Treatment for uterine fibroids: searching for effective drug therapies. Drug Discov Today Ther Strateg. 2012;9:e41–9.CrossRefGoogle Scholar
  8. 8.
    Chang WC, et al. Comparison of laparoscopic myomectomy in large myomas with and without leuprolide acetate. J Minim Invasive Gynecol. 2015;22:992–6.CrossRefGoogle Scholar
  9. 9.
    Muzii L, et al. GnRH analogue treatment before hysteroscopic resection of submucosal myomas: a prospective, randomized, multicenter study. Fertil Steril. 2010;94:1496–9.CrossRefGoogle Scholar
  10. 10.
    Lethaby A, et al. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001;2:CD000547.Google Scholar
  11. 11.
    Fernandez H, et al. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum Reprod. 2004;19:1465–1.CrossRefGoogle Scholar
  12. 12.
    Felberbaum RE, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod. 1998;13:1660–8.CrossRefGoogle Scholar
  13. 13.
    Kettel LM, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril. 1993;60:642–6.CrossRefGoogle Scholar
  14. 14.
    Engel JB, et al. Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study. Eur J Obstet Gynecol Reprod Biol. 2007;134:225–32.CrossRefGoogle Scholar
  15. 15.
    Gonzalez-Barcena D, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 1997;12:2028–35.CrossRefGoogle Scholar
  16. 16.
    Dohan N, et al. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal woman. Eur J Obstet Gynecol Reprod Biol. 2013;171:329–32.CrossRefGoogle Scholar
  17. 17.
    Parsanezhad ME, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93:192–8.CrossRefGoogle Scholar
  18. 18.
    Song H, et al. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013;(10):CD009505.Google Scholar
  19. 19.
    Kriplani A, et al. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116:35–8.CrossRefGoogle Scholar
  20. 20.
    Sayed GH, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112:126–30.CrossRefGoogle Scholar
  21. 21.
    Magalhães J, et al. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75:193–8.CrossRefGoogle Scholar
  22. 22.
    Marui T, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007;75:S99–103.CrossRefGoogle Scholar
  23. 23.
    Catherino WH, et al. Novel, orally active selective progesterone receptor modulator CB8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium. J Steroid Biochem Mol Biol. 2010;122:279–86.CrossRefGoogle Scholar
  24. 24.
    Mutter GL, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–8.CrossRefGoogle Scholar
  25. 25.
    Murphy AA, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab. 1993;76:513–7.PubMedGoogle Scholar
  26. 26.
    Kulshrestha V, et al. Low dose mifepristone in medical management of uterine leiomyoma—an experience from a tertiary care hospital from north India. Indian J Med Res. 2013;137:1154–2.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Esteve JL, et al. Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. Int J Women’s Health. 2013;5:361–9.CrossRefGoogle Scholar
  28. 28.
    Tristan M, et al. Mifepristone for uterine fibroids. Cochrane Database Syst Rev. 2012;8:CD007687.Google Scholar
  29. 29.
    Biglia N, et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther. 2014;8:285–92.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Talaulikar VS, et al. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Devel Ther. 2012;29:655–63.CrossRefGoogle Scholar
  31. 31.
    Fiscella K, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol. 2008;112:707.CrossRefGoogle Scholar
  32. 32.
    Nieman LK, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blinded, placebo-controlled, phase IIb study. Fertil Steril. 2011;95:767–2e1–2.CrossRefGoogle Scholar
  33. 33.
    Donnez J, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–20.CrossRefGoogle Scholar
  34. 34.
    Donnez J, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421–32.CrossRefGoogle Scholar
  35. 35.
    Donnez J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101:1565–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyKyoto Prefectural University of Medicine, Graduate School of Medical ScienceKyotoJapan

Personalised recommendations